05:18 PM EDT, 09/16/2024 (MT Newswires) -- Mark Lappe, Director, Chief Executive Officer, on September 12, 2024, executed a purchase for 40,000 shares in Inhibrx Biosciences ( INBX ) for $629,117. Following the Form 4 filing with the SEC, Lappe has control over a total of 925,413 shares of the company, with 925,413 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/2007919/000200791924000049/xslF345X05/wk-form4_1726521147.xml